Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Exophthalmos Treatment Market Snapshot (2023 to 2033)

The global Exophthalmos Treatment Market is expected to be worth US$ 271.8 Million in the fiscal year 2023, which rose up from US$ 251.2 Million in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 8.2% CAGR, reaching a value of US$ 598 Million by the end of 2033.

Exophthalmos is the term used to describe a condition in which the eyeball bulges outward from the eye socket. Both eyes may be affected or just one. Exophthalmos can result in eye issues such as corneal dryness as well as conjunctivitis, an infection of the interior membrane lining of the eye, depending on how bad it is. In the long run, symptoms usually get better, although it may take years. If therapy is not obtained, it's possible that the eyes will continue to bulge.

Exophthalmos is most often caused by Graves' disease. Around 25 to 50 percent of those who have this illness will also have ocular involvement. It's interesting to note that ocular involvement might happen up to 20 years after a thyroid disorder diagnosis as well as up to 10 years before. Such diseases have been a major driver for exophthalmos treatment from 2023 to 2033.

Along with these causes of the disease, increased research, and development to invent novel drugs for the treatment of exophthalmos disease have been accelerating revenues in the market. The various key players are aimed at developing enhanced medicines and cures, which is also opening up new opportunities for various companies in the global exophthalmos market.

Attributes Details
Anticipated Base Year Value (2022) US$ 251.2 Million
Expected Market Value (2023) US$ 271.8 Million
Projected Forecast Value (2033) US$ 598 Million
Global Growth Rate (2023 to 2033) 8.2%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Exophthalmos Treatment Market Demand Analysis Vs. Forecast 2023 to 2033

The global Exophthalmos Treatment Market grew at a CAGR of 6.4% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

This market is expanding since occurrences of hyperthyroidism and its comorbidities are becoming more common. In addition to the thyroid, exophthalmos can also be brought on by other reasons, such as internal bleeding from an injury in the eye socket.

The introduction of new administration methods that increase therapeutic effectiveness may accelerate market expansion. The industry is growing because researchers are receiving significant financial assistance for creating innovative interventions. As a result, the global Exophthalmos Treatment Market is expected to forecast a CAGR of over 8% from 2023 to 2033.

Prominent Growth Drivers Influencing Exophthalmos Treatment Market

Rising cases of hyperthyroidism are triggering the market expansion

Exophthalmos is mostly brought on by Graves' ophthalmopathy, sometimes referred to as thyroid eye illness. One in three patients with an overactive thyroid is affected by this condition. Smokers as well as middle-aged women are the most likely to experience it.

Around 200 million individuals worldwide suffer from thyroid disorders, primarily hyperthyroidism; in the majority of these nations, 50% of the population goes misdiagnosed. The elderly and women are more likely to suffer from this illness. According to data from the Thyroid Foundation of Canada from 2021, congenital hypothyroidism affects 1 across every 1600 children in Canada. As a result, the market has additional opportunities.

Additionally, a shortage of skilled experts with an understanding of thyroid disease treatment options might support the expansion of the global exophthalmos market over the next few years.

Novel treatment and medicine options to accelerate the growth

It is also anticipated that the introduction of innovative methods of administration that improve the medications' efficacy would restrain the market's expansion for exophthalmos therapy. Additionally, in the upcoming years, there may be more prospects for the expansion of the exophthalmos therapy market due to advancements in antibiotics, nutrition, and innovative treatments.

For instance, Tepezza was authorized by the US Food and Drug Administration (FDA) in 2020 for the treatment of people with exophthalmos. It was the first medication to be authorized for the treatment of exophthalmos. Tepezza has been designated as an orphan medicine, which offers incentives to help and promote the development of medications for uncommon illnesses or ailments. The FDA Orphan Medicines Money Program, which offers grants for clinical investigations on the safety and efficacy of products for use in uncommon illnesses or disorders, also contributed to the development of this medication. As a result, it is anticipated that further research and development will be opening up new avenues for the market players during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Exophthalmos Treatment Market Demand?

Increasing government initiatives and awareness programs impede the global market

As hyperthyroidism is considered to be the primary cause of exophthalmos disease, various governments across nations have been working towards cutting down the incidence of thyroid cases globally. In such a case, with lowering thyroid cases, the cases for exophthalmos will go down as well, hence restraining the market growth during the forecast period.

Collaboration agreements between public and commercial entities have increased, which helps to educate healthcare professionals about thyroid treatment. The American Academy of Otolaryngology, British Thyroid Foundation, American Thyroid Association (ATA), and Thyroid Foundation of Canada are just a few of the government groups that are actively raising awareness of the condition and its available treatments. These kinds of steps are expected to hinder market expansion from 2023 to 2033.

Region-wise Analysis 

What is the outlook of the North American Exophthalmos Treatment Market?

Rising incidence of thyroid cases along with novel drugs development will boost the growth

During the forecast period, the North American market for exophthalmos disease is expected to be the most volatile one. As per Future Market Insights, this region is expected to prolifer with a robust CAGR of 8.7% from 2023 to 2033.

North America is anticipated to lead the market due to important factors such as the rising incidence of different thyroid illnesses in the USA as well as the development of novel treatment options. Around 18 in 100,000 Americans have exophthalmos disease, as per data from the American Academy of Ophthalmology that was released in July 2022. As a result, the expansion of the market under investigation in the area will be aided by the exophthalmos disease's prevalence in the USA.

The market for exophthalmos illness is expanding as a result of notable product releases, a high proportion of market participants, and the presence of companies in the US. For example, in January 2020, Horizon Therapeutics PLC reported that the Food and Drug Administration approved TEPEZZA to treat exophthalmos disease. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.

What can be expected from the Asia Pacific market for Exophthalmos Treatment?

Increasing cases of Grave’s disease along with thyroid cases accelerate the growth

During the forecast period, the Asia Pacific market for Exophthalmos Treatment is expected to garner a steady CAGR of 7.1%.

Countries like China and India were reported to have most of the exophthalmos cases in the Asia Pacific region. For instance, in India, one of the most prevalent endocrine conditions affecting roughly 42 million Indians is thyroid disease. And about 31% of these people eventually start to experience exophthalmos disease symptoms. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which treatment segment is expected to gain traction from 2023 to 2033?

The non-surgical segment will gain the dominant market share

Over the course of the forecast period, the non-surgical segment by treatment type is anticipated to occupy a significant share of the global exophthalmos treatment market. In 2023, this category is anticipated to dominate with a 53% revenue share.

Whenever the patients start experiencing the symptoms of bulging out of the eyes, immediately they reach out to the ophthalmologist, who mostly prescribes certain eye drops and antibiotics. With the advancements in medications, there are now certain eye drops that have steroids as well to immediately bring the eyeball back to normal size. Hence, in such a scenario, no surgery is required. Such factors are expected to accelerate the growth prospects for exophthalmos treatment from 2023 to 2033.

Which end-user segment is expected to gain traction from 2023 to 2033?

The specialty clinics segment will demand during the forecast period.

According to the research by Future Market Insights, the specialty clinic segments will gain traction during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.

During a case of exophthalmos, patients prefer visiting an eye clinic, rather than a hospital. These specialty clinics offer patients a wide range of treatment options as well as doctors. At the same time, treatment over here is quite affordable when compared to that of a hospital. Hence, during the forecast period, this segment is expected to acquire more than half of the global exophthalmos market in 2023.

Start-up Scenario

The newly founded businesses in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.

  • GenSight Biologics is a biotechnology business in the clinical stages of research and development that identifies and creates innovative treatments for neurodegenerative as well as mitochondrial illnesses of the eye and the central nervous system. They utilize their integrated development platform to tackle these therapeutic areas by integrating a gene therapy-based strategy with our primary technological platforms, mitochondrial targeting sequence, and optogenetics.
  • Leading AI diagnostics business IDx is on a quest to improve the standard, availability, and cost of healthcare. The company's initial offering, IDx-DR, is an automation diagnostic system with FDA clearance for use in the field to identify diabetic retinopathy. For the diagnosis of macular degeneration, exophthalmos, Alzheimer's disease, glaucoma, cardiovascular disease, and stroke risk, IDx is creating more AI-based diagnostic algorithms.

Competitive Landscape 

Some of the prominent players in the global market for Exophthalmos Treatment are:

  • Eyevance Pharmaceuticals
  • Sling Therapeutics
  • Competition Deep Dive
  • AbbVie
  • Alcon
  • Avik Pharma
  • Anuh Pharma Ltd.
  • Pfizer CentreOne
  • Pipelinepharma
  • Mylan N.V.
  • Manus Aktteva Biopharma LLP
  • Roche

Some of the prominent developments of the key players in the market are:

  • In 2019, Eyevance Pharmaceuticals announced that it has purchased Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% as well as Natacyn (natamycin ophthalmic suspension) 5% from Novartis. The purchase of Tobradex ST and Natacyn is the most recent development in Eyevance's expansion plan, which also included the license or purchase of other ophthalmic pharmaceutical goods in 2017 and 2018.
  • A biopharmaceutical business called Sling Therapeutics, Inc. announced its formal launch in 2022 with a $35 million Series A investment led by TPG's The Rise Fund. The company is focused on late-stage research of an oral small molecule for the treatment of exophthalmos. The money will go toward Phase 2b clinical research examining the effectiveness of linsitinib, an experimental medication from the business, in treating exophthalmos disease.

Scope of Report

Report Attribute Details
Growth Rate CAGR of 8.2% from 2023 to 2033
Market value in 2023 US$ 271.8 Million
Market value in 2033 US$ 598 Million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units USD Million for Value
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • End-user
  • Region
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Key Countries Profiled
  • United States of America
  • Canada
  • Mexico
  • Brazil
  • Germany
  • Italy
  • France
  • United Kingdom
  • Spain
  • Poland
  • Russia
  • China
  • India
  • ASIAN
  • Australia
  • New Zealand
  • Japan
  • GCC Countries
  • S. Africa
  • Northern Africa
Key Companies Profiled
  • Spectra Vision Care
  • AbbVie
  • Alcon
  • Avik Pharma
  • Anuh Pharma Ltd.
  • Pfizer CentreOne
  • Pipelinepharma
  • Mylan N.V.
  • Manus Aktteva Biopharma LLP
  • Roche
  • Eyevance Pharmaceuticals
  • Sling Therapeutics
Customisation Scope Available on Request

Key Segments Covered In The Exophthalmos Treatment Market Report

Exophthalmos Treatment Market By Treatment:

  • Non-surgical Treatment
    • Sympathomimetic Amines
    • Corticosteroids
    • Secondary Metabolites
    • Monoclonal Antibodies
    • Radiotherapy
  • Surgical Treatment
    • Orbital Decompression
    • Eye Muscle Surgery
    • Eyelid Surgery

Exophthalmos Treatment Market By End User:

  • Hospital Pharmacies
  • Specialty Clinics
  • Others

Exophthalmos Treatment Market By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa (MEA)

Frequently Asked Questions

How Much the Market is Slated to Attain?

The market is slated to attain US$ 271.8 million in 2023.

At What Speed, the Market is Expected to Expand?

The market is expected to expand at a CAGR of 8.2% through 2033.

Which Factors are Facilitating Market Growth?

Novel treatment and medicine options are catapulting the market growth.

Which Factors are Causing Hinderance for Market Growth?

Increasing steps to lower the emergence of exophthalmos through government programs is expected to cause hinderance for market.

What is North America’s Scope for Growth?

North America is expected to expand at a CAGR of 8.7%.

Table of Content

1. Executive Summary | Exophthalmos Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Non-surgical Treatment

            5.3.1.1. Sympathomimetic Amines

            5.3.1.2. Corticosteroids

            5.3.1.3. Secondary Metabolites

            5.3.1.4. Monoclonal Antibodies

            5.3.1.5. Radiotherapy

        5.3.2. Surgical Treatment

            5.3.2.1. Orbital Decompression

            5.3.2.2. Eye Muscle Surgery

            5.3.2.3. Eyelid Surgery

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Specialty Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa (MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States of America

            8.2.1.2. Canada

        8.2.2. By Treatment

        8.2.3. By End Users

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment

        8.3.3. By End Users

    8.4. Key Takeaways

9. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment

        9.2.3. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By End Users

    9.4. Key Takeaways

10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment

        10.2.3. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By End Users

    10.4. Key Takeaways

11. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Treatment

        11.2.3. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By End Users

    11.4. Key Takeaways

12. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Treatment

        12.2.3. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By End Users

    12.4. Key Takeaways

13. Key Countries Analysis

    13.1. United States of America

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Treatment

            13.1.2.2. By End Users

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Treatment

            13.2.2.2. By End Users

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Treatment

            13.3.2.2. By End Users

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Treatment

            13.4.2.2. By End Users

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Treatment

            13.5.2.2. By End Users

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Treatment

            13.6.2.2. By End Users

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Treatment

            13.7.2.2. By End Users

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Treatment

            13.8.2.2. By End Users

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Treatment

            13.9.2.2. By End Users

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Treatment

            13.10.2.2. By End Users

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Treatment

            13.11.2.2. By End Users

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Treatment

            13.12.2.2. By End Users

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Treatment

            13.13.2.2. By End Users

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Treatment

            13.14.2.2. By End Users

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Treatment

            13.15.2.2. By End Users

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Treatment

            13.16.2.2. By End Users

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Treatment

            13.17.2.2. By End Users

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Treatment

            13.18.2.2. By End Users

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Treatment

            13.19.2.2. By End Users

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Treatment

            13.20.2.2. By End Users

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Treatment

        14.3.3. By End Users

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Spectra Vision Care

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. AbbVie

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Alcon

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Avik Pharma

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Anuh Pharma Ltd.

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Pfizer CentreOne

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Pipelinepharma

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Mylan N.V.

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Manus Aktteva Biopharma LLP

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Roche

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

Helicobacter Pylori Infections Treatment Market

Published : December 2022

Healthcare

Eye Infections Treatment Market

Published : July 2022

Explore Healthcare Insights

View Reports

Exophthalmos Treatment Market